Compare
Oncolytics Biotech Inc vs Ensysce Biosciences, Inc. vs Processa Pharmaceuticals, Inc. vs Cannapharmarx, Inc.
| Latest fiscal year | Oncolytics Biotech Inc ONCY | Ensysce Biosciences, Inc. ENSC | Processa Pharmaceuticals, Inc. PCSA | Cannapharmarx, Inc. CPMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $5.07M | n/a | $1.36M |
| Revenue growth (YoY) | n/a | -2.8% | n/a | +66.1% |
| Gross margin | n/a | n/a | n/a | -153.1% |
| Operating margin | n/a | -202.1% | n/a | -245.8% |
| Net margin | n/a | -200.8% | n/a | -817.2% |
| Net income | -$28.76M | -$10.18M | -$13.56M | -$11.13M |
| EPS (Diluted) | -$0.30 | -$3.98 | -$10.36 | -$0.02 |
| Operating cash flow | -$20.11M | -$7.81M | -$11.39M | -$789.1K |
| Free cash flow | -$20.12M | -$7.93M | n/a | -$794.6K |
| Cash & equivalents | $5.20M | $4.31M | $5.54M | $1.8K |
| Total assets | $7.58M | $7.45M | $7.81M | $7.02M |
| Total liabilities | $11.38M | $4.57M | $2.24M | $37.17M |
| Shareholders' equity | -$3.80M | $3.21M | $5.58M | -$30.15M |
| Return on year-end equity | n/a | -316.6% | -243.2% | n/a |
| Shares outstanding | 108.02M | 4.57M | 2.57M | 662.50M |
Revenue, most recent five fiscal years
| Fiscal year | Oncolytics Biotech Inc | Ensysce Biosciences, Inc. | Processa Pharmaceuticals, Inc. | Cannapharmarx, Inc. |
|---|---|---|---|---|
| Latest | n/a | $5.07M Ended 2025-12-31 | $0 Ended 2022-12-31 | $1.36M Ended 2025-12-31 |
| 1 year earlier | n/a | $5.21M Ended 2024-12-31 | $0 Ended 2021-12-31 | $820.1K Ended 2024-12-31 |
| 2 years earlier | n/a | $2.23M Ended 2023-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $2.52M Ended 2022-12-31 | n/a | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $3.53M Ended 2021-12-31 | n/a | $0 Ended 2021-12-31 |